Search

You searched for "registrars"

511 results found

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

1 January 2016 | | URO - Urologic Oncology, URO - Technology
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

JCST, GMC, HEE and SACs: how this alphabet soup translates into a seven-year urology training programme

8 December 2021 | | URO - Core Urology
As many trainees will know, and I count myself among them, there are a plethora of organisations involved in our training. Most of us will be familiar with our deaneries, the haven we return to once a month for our...

Reviews

ABC (Action Bladder Cancer) UK Annual Nurses Education Day: Understanding Bladder Cancer and the Latest Developments

5 September 2025
Action Bladder Cancer UK is holding its next annual Nurses’ Education Day for Urology Nurses and Clinical Nurse Specialists in Birmingham on Friday 5th September 2025. This is ABC UK’s fourth full day education event for nurses, following the success...

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

1 July 2017 | | URO - Urologic Oncology
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...

Fluoroquinolone resistant rectal colonisation predicts risk of infectious complications after TRPB

1 March 2015 | | URO - Basic Science Research
Transrectal prostate biopsy (TRPB) has been associated with increased risk of infection between 3.6-5% and sepsis rates of 0.3-3.1% mainly due to fluoroquinolone resistance (FQR). At present, FQ antibiotic prophylaxis is utilised commonly across North America and Europe but due...

The burning issue of urinary tract infections

1 September 2018 | | URO - Infection, URO - Functional / Reconstructive Urology
Urinary tract infections (UTIs) occur when bacteria colonise and proliferate in the urinary tract. These are characterised by specific clinical symptoms (dysuria, suprapubic tenderness, urgency and urinary frequency) which commonly occur alongside the finding of bacteriuria. UTIs are common –...

New eco-friendly home delivery service launched! - May 2021

4 May 2021 | Research & Development
Optimum Medical celebrate the launch of their new eco-friendly home delivery service, Vyne. Vyne is here to provide a better, greener and easier way of getting your patients’ healthcare appliances and prescription medication delivered direct to their door.

25 Years of Prostate Cancer UK

8 February 2022 | | URO - Urologic Oncology
As leading men’s health charity, Prostate Cancer UK, celebrates its 25th anniversary, top researchers reflect on the huge progress in testing, treatment and support for men over the past 25 years. 25 years of beating prostate cancer together Matthew Hobbs,...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

So you want to go on a fellowship – part II: the research year

1 November 2016 | | URO - Core Urology
This article is the second in a three-part series which follows directly on from the first part which concentrated on the rationale for going on a fellowship, as well as some of the administrative hurdles you might face in planning...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...